Glaxo Subsidiary Stiefel’s Former CEO Faces Securities Fraud Charges
By
Malcolm Spicer / Email the Author / “The Tan Sheet” Dec. 19, 2011, Vol. 19, No. 51
Regulatory / Word Count: 1343 / Article # 05111219002
Executive Summary
The Securities and Exchange Commission alleges Charles Stiefel, former chairman and CEO of family-owned Stiefel Labs, did not disclose to employee-shareholders material information on the value of the firm’s shares as the firm bought back shares before being acquired by GlaxoSmithKline.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.